From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

Breakthrough Discovery on Target to Block Staphylococcus Infection

by Global Biodefense Staff
February 11, 2013

Neutrophil (purple) ingesting Staphylococcus aureus bacteria (yellow)National Institutes of Health (NIH) scientists have identified a promising lead for developing a new type of drug to treat infection caused by Staphylococcus aureus, a bacterium that frequently resists traditional antibiotics. 

Interfering with crucial virulence determinants is considered a promising new approach to control bacterial infection. Prior research targeting therapeutic intervention of Phenol-soluble modulins (PSMs), peptide toxins with multiple key roles in pathogenesis and impact of virulent S. aureus, has been hampered by their multitude and diversity. 

Scientists at the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) have now discovered that an ATP-binding cassette transporter with previously unknown function is responsible for the export of PSMs, thus representing a single target for complete obstruction of PSM production. This transport system, which the team calls Pmt, is common to all S. aureus PSMs and critical for bacterial proliferation and disease development. 

The team’s experiments suggest that a drug interfering with Pmt’s function could not only prevent production of the PSM toxins, but also directly lead to bacterial death. Although their study focused on S. aureus, the scientists suspect that Pmt performs the same role in other staphylococci, such as S. epidermidis, the leading cause of hospital-associated infections involving indwelling medical devices such as catheters, pacemakers and prosthetics. 

The team plans to continue their studies to improve the understanding of how PSMs function and to learn how to interfere with the Pmt transport system to block disease. Study results will appear this week in Nature Medicine: Essential Staphylococcus aureus toxin export system.

Image courtesy of NIAID

From Our Partners

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC